Novo Nordisk's Obesity Market Share Squeeze: Can It Defend Its Scaling Edge Against Lilly?

Novo Nordisk's growth story is built on a simple, powerful premise: it is capturing a massive, expanding market for obesity and diabetes treatments. The company's core thesis is not about incremental gains, but about scaling dominance in a field where unmet need is vast and the market is only beginning to open. The total addressable market here is staggering, with almost 1 billion people living with obesity and around 600 million living with diabetes. This isn't a niche opportunity; it's a global health challenge that translates directly into a colossal commercial runway.

The company's execution in 2025 provides a clear blueprint for this scaling. While overall sales grew 6% in local currency, the real engine was the 26% increase in Obesity care product sales, which accelerated to 31% at constant exchange rates. This wasn't just growth; it was market leadership in action, with Novo Nordisk holding a 59.6% branded volume share of the global GLP-1 obesity market. The business model is proving highly scalable, as evidenced by the 104% volume growth in that entire market segment. Novo Nordisk is not just selling more pills; it is systematically expanding the market itself.

This scalability extends beyond just sales volume. The company is aggressively building the manufacturing capacity needed to meet this surging demand. While the 2025 report notes a 32% increase in cost of goods sold that pressured gross margins, that surge is a direct cost of scaling production. It reflects the investment in facilities and processes required to produce the next generation of obesity and diabetes therapies. This is the classic trade-off of a scaling business: near-term margin pressure in exchange for securing long-term market share and revenue growth.

The strategic focus reinforces this growth thesis. The company has shifted from expansion into new therapy areas toward going deeper into its core areas of Obesity and Diabetes. This means concentrating R&D, manufacturing, and commercial resources where the largest, fastest-growing markets are. By doubling down on these two pillars, Novo Nordisk is optimizing its ability to capture the vast majority of the expanding pie. The path is clear: leverage its leadership in GLP-1s to drive obesity sales, while using its cardiorenal focus to strengthen its diabetes portfolio, all while building the capacity to serve the billions of patients still underserved.

Competitive Positioning and Pipeline Catalysts

The competitive landscape is shifting, and Novo Nordisk is facing a clear market share challenge. While it played a pivotal role in making GLP-1 drugs mainstream, Eli Lilly has since taken a clear edge in market share. This divergence is now reflected in their 2026 outlooks, with Lilly guiding for revenue growth while Novo braces for a sales decline. The split underscores the strength of Lilly's position, bolstered by its more effective injections and early direct-to-consumer sales strategy. For a growth investor, this signals a period of intense competition where capturing and holding share will be paramount.

Pricing pressure in the U.S. is a shared headwind, but the company's response and pipeline strength will determine its long-term trajectory. The key differentiator lies in clinical data. Recent real-world evidence from the STEER study suggests a potential edge for Novo's semaglutide. The analysis found that Wegovy users had a 57% greater reduction in the risk of major cardiovascular events compared with those on tirzepatide. This clinical differentiator is a powerful tool for commercialization, offering a tangible reason for physicians and payers to choose Novo's products. It reinforces the value proposition beyond just weight loss, targeting the significant cardiovascular comorbidities that drive demand.

Beyond this, the pipeline remains a critical source of future growth, even after setbacks. The company is advancing a robust innovation engine focused on multi-target medicines. Key assets in phase 3 include CagriSema, a once-weekly combination therapy, and zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist. These dual and triple agonists aim to deliver stronger, more comprehensive outcomes. The recent approval of a higher-dose Wegovy and the Wegovy pill also demonstrates the pipeline's ability to deliver breakthrough results, expanding the addressable market for oral and higher-dose options.

Looking ahead, near-term catalysts are concentrated in regulatory and clinical milestones. The company is awaiting FDA decisions on several semaglutide indications, including Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity. Securing these new approvals would directly expand the patient population and reinforce the molecule's clinical versatility. At the same time, the market will be watching how Novo's oral Wegovy performs against Lilly's upcoming obesity pill, orforglipron. This upcoming launch is a direct test of Novo's ability to defend its market share in the oral segment, a crucial battleground for future growth.

Financial Impact, Valuation, and Forward Scenarios

The financial story for Novo Nordisk is one of scaling pressure meeting a massive market. The 2025 results showed the power of that growth engine, with sales hitting DKK 309,064 million ($45.9 billion) and operating profit up 6% at constant exchange rates. Yet the path ahead is fraught with near-term headwinds that have already shaken investor confidence. The stock's sharp decline following the February earnings report, despite beating EPS expectations, signals that the market is pricing in a difficult 2026. The company itself is forecasting a sales and profit contraction, a direct result of intensifying pricing pressures in the U.S. market and a competitive shift where Eli Lilly has taken a clear edge in market share.

This sets up a clear valuation puzzle. On one hand, the stock has pulled back significantly, with a 58.3% return over the last year lagging behind its peers. On the other, the business is still generating immense cash flow, returning DKK 52 billion to shareholders in 2025 and targeting over DKK 60 billion in 2026. A discounted cash flow analysis suggests a fair value significantly above recent prices, implying the market may be discounting the company too harshly for near-term pain. The key is whether this discount is justified by a structural loss of growth or simply a cyclical adjustment to a more competitive landscape.

The forward trajectory hinges on three interconnected scenarios. First, market expansion remains the ultimate driver. The company's ability to capture a larger share of the global obesity and diabetes markets, estimated at nearly 1 billion and 600 million people respectively, will determine long-term revenue. This depends on manufacturing scale and commercial execution, which are currently under pressure. Second, next-generation therapies are the critical catalyst for sustaining growth beyond the current GLP-1 wave. The success of upcoming approvals like Wegovy SC for heart failure and the launch of oral Wegovy will be pivotal. More importantly, the clinical differentiation of pipeline assets like CagriSema and zenagamtide could re-establish a leadership edge. Third, pricing pressures are the immediate overhang. The divergence in 2026 outlooks with Lilly shows this is not just a company-specific issue but a market-wide dynamic. Novo's response will be tested when Lilly's orforglipron pill enters the market, directly challenging Novo's oral segment.

The bottom line for a growth investor is a bet on scale versus competition. The current valuation offers a margin of safety, but the stock's trajectory will be dictated by whether Novo can defend its market share, successfully launch new products, and navigate pricing to maintain its path toward the vast total addressable market. The next 12 to 18 months will provide the first clear signals on which scenario is taking hold.